Monday, January 25, 2021
Home Other Biostatistics: a panacea for clinical data analysis

Biostatistics: a panacea for clinical data analysis

By Chrins Thomas Jojo

Biostatistical analysis is a key factor in conducting clinical research and is one of the solid foundation for evidence based clinical practice.

- Advertisement -

A biostatistician uses mathematics and statistics to develop methods to provide formal accounting for sources of variability in patients response to treatment.

It includes collection, analysing, presenting and interpreting data. It is applied in various fields like epidemiology, clinical trials, population genetics and system biology.

Biostatistics play a major role in preventing fraud or unintentional errors during clinical research. Biostatistics is a critical factor in developing public health policy and data management.

The use of biostatistics in public health can use data for several applications. It includes the use of data for population based interventions, use of data for identifying barriers to care, using data to influence public policy and to evaluate a program’s impact.

The revolution of P value has made the scope and use of biostatistics leap in bounds. P value is been used widely in investigating proposed medical treatments, assessing the relative benefits of competing therapies, establishing optimal treatment combinations.

One goal in conducting statistics based studies is to build a sound evidence base for clinical care. It is also useful in conducting epidemiological studies especially during pandemics.

It also helps in calculating sampling, determining the power of a study, result interpretation, measuring random errors, minimising biases.

Biostatistician can work in a variety of fields. It includes the academic fields, government, non-profit organizations, pharmaceutical companies or contracted research organizations;

1.Business and Industry

2. Statistical computing

3.Health and medicine in various fields like the epidemiology, pharmacology, public health and in the field of genetics.

4. Learning and research – It includes education, science writing and journalism, government sector and the survey methods as well.

5. Social statistics and natural resources includes law, consulting, agriculture and ecology.

Typical activity of a biostatistician includes

  • Sample size requirement
  • Analysis plan at design stage
  • Randomization
  • Sampling design
  • Statistical analysis

 Data science and biostatistics are two sides of a coin. Biostatistics is imperative in binding the data collected in bits.

Data scientist must have  deep understanding of statistical concepts in order to carry out quantitative analysis on available data.

The future of biostatistics is safe and will be seeing a huge growth in the upcoming years as data analytics and management has already been a part of our daily life.

Also, A noteworthy future for biostatistics is awaiting as its the major league in clinical data management and clinical research.


  2. The role of biostatistics in the prevention, detection and treatment of fraud in clinical trials  marc buyse1*, stephen l. George2, stephen evans3, nancy l. Geller4, jonas ranstam5, bruno scherrer6, emmanuel lesaffre7, gordon murray8, lutz edler9, jane hutton10, theodore colton11, peter lachenbruch12 and babu l. Verma13


    Please enter your comment!
    Please enter your name here

    14 + 13 =

    Most Popular

    Calquence approved in Japan for the treatment of relapsed or refractory chronic lymphocytic leukaemia

    January 25, 2021: "AstraZeneca’s Calquence (acalabrutinib), a next-generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult...

    What is the process for Submission of Synopsis?

    1.1 a. "Prior to submission of a thesis synopsis, a comprehensive assessment of the research work should be carried out by a...

    COVAX Announces new agreement, plans for first deliveries

    January 22, 2021: COVAX, the global initiative to ensure rapid and equitable access to COVID-19 vaccines for all countries, regardless of income...

    FDA Approves OPDIVO® with CABOMETYX® as First-line Treatment for advanced Renal Cell Carcinoma

    22 Jan 2021:  Bristol Myers Squibb announced that OPDIVO®(nivolumab) 240 mg (injection for intravenous use) every two weeks or 480 mg every four weeks...